DADC
NAGE

D.A. Davidson & Co’s Niagen Bioscience NAGE Stock Holding History

D.A. Davidson & Co’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$820 – 1601
2025
Q2 		$820 Sell
1
-1
-50% -$10 ﹤0.01% 1444
2025
Q1 		$360 Buy
+2
New +$13 ﹤0.01% 1403

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.A. Davidson & Co's NAGE Position: Q4 2025 in Review

D.A. Davidson & Co sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 26,942 shares — an estimated $251K sold.

D.A. Davidson & Co first reported a position in NAGE in Q2 2016 and held it in 26 quarters. The position peaked at $533K in Q2 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

  • D.A. Davidson & Co reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 26,942 Niagen Bioscience shares in Q4 2025, an estimated $251K.
  • D.A. Davidson & Co first reported a position in Niagen Bioscience in Q2 2016 and held it in 26 quarters.
  • D.A. Davidson & Co's Niagen Bioscience position peaked at $533K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on D.A. Davidson & Co's 13F filing for Q4 2025, filed 29 Jan 2026.